News & Updates

Insomnia in children with ADHD affects daytime behaviour and cognitive functioning
Insomnia in children with ADHD affects daytime behaviour and cognitive functioning
28 Jun 2022 byKanas Chan

Insomnia may play a role in manifestation of attention deficit hyperactivity disorder (ADHD) symptoms and has a negative effect on cognitive abilities of children with ADHD, according to a cross-sectional study by the University of Hong Kong (HKU), the Chinese University of Hong Kong (CUHK) and Alice Ho Miu Ling Nethersole Hospital. 

Insomnia in children with ADHD affects daytime behaviour and cognitive functioning
28 Jun 2022
Response analysis further establishes tezepelumab benefit in severe uncontrolled asthma
Response analysis further establishes tezepelumab benefit in severe uncontrolled asthma
27 Jun 2022 byRoshini Claire Anthony

Adolescents and adults with severe uncontrolled asthma while on inhaled corticosteroids (ICS) had greater responses to the human monoclonal antibody tezepelumab than placebo, according to prespecified exploratory results of the phase III NAVIGATOR trial.

Response analysis further establishes tezepelumab benefit in severe uncontrolled asthma
27 Jun 2022
Pharmacist intervention confers benefits on cardiovascular outcomes
Pharmacist intervention confers benefits on cardiovascular outcomes
27 Jun 2022

Pharmacist interventions help improve cardiovascular disease management, including risk factor control, better medication adherence, and reduction in morbidity and mortality, a study has found.

Pharmacist intervention confers benefits on cardiovascular outcomes
27 Jun 2022
COPD tied to earlier lung cancer diagnosis
COPD tied to earlier lung cancer diagnosis
27 Jun 2022 byAudrey Abella

Chronic obstructive pulmonary disease (COPD) is associated with an earlier diagnosis of lung cancer, according to a cross-sectional, real-world study.

COPD tied to earlier lung cancer diagnosis
27 Jun 2022
Infliximab, adalimumab biosimilars effective, safe in paediatric IBD
Infliximab, adalimumab biosimilars effective, safe in paediatric IBD
27 Jun 2022 byTristan Manalac

The use of biosimilars of infliximab (IFX) and adalimumab (ADA) is both safe and effective in children with inflammatory bowel disease (IBD), inducing high rates of failure-free survival with a low incidence of adverse events, according to a study presented at the 2022 Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN 2022).

Infliximab, adalimumab biosimilars effective, safe in paediatric IBD
27 Jun 2022